• About
  • Alzosure Test
  • Alzosure Predict
  • Literature
  • Publications
  • Board of Directors
  • Team
  • MAB
  • Partners
  • News
  • Diadem US Inc
  • About
  • Alzosure Test
  • Alzosure Predict
  • Literature
  • Publications
  • Board of Directors
  • Team
  • MAB
  • Partners
  • News
  • Diadem US Inc

Diadem Names Clinical Diagnostics Industry Veteran Paul Kinnon as CEO

by Claire | Oct 23, 2022 | Uncategorized

DIADEM NAMES CLINICAL DIAGNOSTICS INDUSTRY VETERAN PAUL KINNON AS CEO —Kinnon Joins to Lead Development and Commercialization of First Minimally Invasive Blood-Based Prognostic Test for Early Alzheimer’s Disease—   —Accessible Early Diagnosis Will Transform...

Development of Blood-Based Alzheimer’s Prognostic Propels Diadem to Finalist Status for Both the Gaetano Marzotto Company Prize and 2030 Social Impact Special Prize

by Claire | Oct 23, 2022 | Uncategorized

DEVELOPMENT OF BLOOD-BASED ALZHEIMER’S PROGNOSTIC PROPELS DIADEM TO FINALIST STATUS FOR BOTH THE GAETANO MARZOTTO COMPANY PRIZE AND 2030 SOCIAL IMPACT SPECIAL PRIZE —Prestigious Awards Celebrate Entrepreneurial Company Innovation and Pioneering New Products Supporting...

Diadem Names Dr. Tamas Bartfai Chair of Its Medical Advisory Board

by Claire | Oct 23, 2022 | Uncategorized

DIADEM NAMES DR. TAMAS BARTFAI CHAIR OF ITS MEDICAL ADVISORY BOARD —Dr. Bartfai Brings Broad Academic and Pharma Industry Experience to Medical Advisory Board Comprised of Distinguished Alzheimer’s Disease Researchers and Opinion Leaders — Milan, ITALY – December 1,...

Diadem Presents Clinical Data and Commercialization Plans for Its AlzoSure® Prognostic Biomarker Test at 2020 Alzheimer’s Disease International Conference

by Claire | Oct 23, 2022 | Uncategorized

DIADEM PRESENTS CLINICAL DATA AND COMMERCIALIZATION PLANS FOR ITS ALZOSURE® PROGNOSTIC BIOMARKER TEST AT 2020 ALZHEIMER’S DISEASE INTERNATIONAL CONFERENCE —Blood-Based AlzoSure Assay Has Potential to Transform Management of Alzheimer’s Disease by Identifying Patients...

New Scientific Publications Show Diadem’s Blood-Based AlzoSure® Biomarker Test Can Predict Which Patients Will Progress to Alzheimer’s Disease Years Before Symptoms Occur

by Claire | Oct 23, 2022 | Uncategorized

NEW SCIENTIFIC PUBLICATIONS SHOW DIADEM’S BLOOD-BASED ALZOSURE® BIOMARKER TEST CAN PREDICT WHICH PATIENTS WILL PROGRESS TO ALZHEIMER’S DISEASE YEARS BEFORE SYMPTOMS OCCUR —Published Studies Explore How a Variant of p53 Contributes to the Development of Alzheimer’s...

Diadem Presents New Data at AAIC® Symposium Showing Its Blood-Based Biomarker Test Accurately Predicts Progression to Alzheimer’s Disease 7 Years Before Symptoms Occur

by Claire | Oct 23, 2022 | Uncategorized

DIADEM PRESENTS NEW DATA AT AAIC® SYMPOSIUM SHOWING ITS BLOOD-BASED BIOMARKER TEST ACCURATELY PREDICTS PROGRESSION TO ALZHEIMER’S DISEASE 7 YEARS BEFORE SYMPTOMS OCCUR —Analysis of 224 Longitudinal Patient Samples Confirms Diadem’s Prognostic Biomarker Can Predict...
« Older Entries
Next Entries »

Recent Posts

  • Diadem and the University of Texas Medical Branch report new evidence on Alzheimer’s biomarker at CTAD 2026
  • Diadem awarded US patent for AlzoSure® Alzheimer’s disease prediction technology
  • Seed Healthcare Leads Strategic Investment in Diadem
  • Diadem Unveils Novel Findings on Early Alzheimer’s Disease Detection Using p53-Specific Antibody at CTAD 2024
  • Diadem Appoints Michael Rasche as Chief Executive Officer

Recent Comments

No comments to show.

Blood-based diagnostics for early detection of Alzheimer’s disease

Legal Headquarters:
Diadem S.p.A.
Via Ceresio 7
Milano, Italy

Diadem US, Inc
1117 S.California Avenue
Palo Alto , CA94304

Diadem GmbH
Faberstrasse 8D
81373 München, Germany

Email: execadmin@diademdx.com

Diadem tests are not approved under any geography

SITE MAP

  • Home
  • About
  • AlzoSure Test
  • AlzoSure Predict
  • Literature
  • Publications
  • Board of Directors
  • Team
  • MAB
  • Partners
  • News
  • Diadem US Inc

Copyright © 2026 All Rights Reserved by Diadem S.p.A.  |  Privacy Policy  |  Cookie Policy